It was the final day of this truly wonderful global congress.
Chloe Orkin of the Department of Infection and Immunity at the London Hospital co-chaired the opening session of the day and discussed some great advances in HIV research this year including:
. Phase 3 TDF v TAF trials
. Injectable PrEP
. ?generic 3TC/TDF
. New delivery methods
. New molecules
Sheena McCormack of the MRC clinical trials unit at University College London provided us with PrEP updates and effectiveness, highlighting:
. the overwhelming evidence of its efficacy
. Population effectiveness not compromised by resistance
Based on the evidence, she concluded that moving into the future, there will be more drug choices for PrEP, different regimen choices (episode driven) and a multitude of delivery methods (vaginal rings/injectables).
One of the day's most thought provoking presentations was delivered by Keith Rawlings from Gilead Sciences medical affairs. He reported that despite a steady increase in PrEP use since 2012, data showed there was a huge discrepancy in those who accessed it. He stayed that it was heavily weighted towards middle class caucasian MSM.
This was despite an increased lifetime risk of HIV acquisition of:
. 1:20 for African American males
. 1:48 for African American women
. 1:48 Hispanic males
And when broken down further:
. 1:2 African American MSM
. 1:4 Hispanic MSM
as compared to 1:11 in Caucasian MSM
FTC/TDF for PrEP has been disproportionately low in the higher risk populations in the USA.
It was recommended that to effectively decrease new HIV infections, messaging and services need to be more focused on those populations with the greatest disease burden.
It's been an incredible 4 days here in Glasgow which has sadly come to an end. I look forward with great anticipation to the next Glasgow HIV Drug Therapy Congress 2018 and anticipate further advances will continue globally in HIV management thanks to the many innovative and brilliant researchers working in the field.